查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024890

免疫調節劑市場報告：按產品、應用和地區分類（2026-2034 年）

Immunomodulators Market Report by Product (Immunosuppressants, Immunostimulants), Application (Oncology, Respiratory, HIV, and Others), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2025年全球免疫調節劑市場規模達2,325億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到3,482億美元，2026年至2034年的複合年成長率為4.45%。

免疫調節劑是一類用於調節身體對感染疾病、免疫力缺乏和異常抗體轉移的免疫反應的藥物。這些藥物通常包括單株抗體、細胞激素、左旋咪唑和卡介苗（BCG）。它們廣泛用於治療癌症、氣喘、腫瘤、遺傳性血管性水腫以及自體免疫疾病，例如天皰瘡、紅斑性狼瘡、過敏症和類風濕性關節炎。許多醫療專業人員現在建議將免疫調節劑與其他藥物（例如生物製藥）合併使用，以治療發炎性腸道疾病（IBD）。

免疫調節藥物市場趨勢：

快速的都市化、收入水準的提高以及加工食品消費增加所導致的不健康生活方式，正推動全球慢性病盛行率顯著上升。這進一步增加了器官移植的需求，從而對作為器官移植受者潛在治療手段的局部免疫調節劑產生了積極影響。此外，人口老化和事故發生率的上升也增加了器官衰竭的風險。因此，許多政府機構和私人組織都在鼓勵器官捐獻，這促進了全球局部免疫調節劑市場的發展。此外，發炎性腸道疾病（IBD）和自體免疫疾病盛行率的上升也推動了市場成長。免疫調節劑也被用作聯合治療，以減少長期使用類固醇、預防復發以及治療對抗生素無反應的感染疾病。此外，一些免疫調節劑，例如Baricitinib合併氟伏沙明、托珠單抗和瑞德西韋，正被用於治療新冠肺炎住院患者。此外，目前有多個候選產品正處於後期臨床試驗階段。這些產品的研發有望擴大免疫調節劑在治療各種危及生命的疾病的應用範圍。

本報告解答的主要問題

  • 全球免疫調節藥物市場目前的發展狀況如何？未來幾年我們預計會看到哪些趨勢？
  • 新冠疫情對全球免疫調節藥物市場產生了哪些影響？
  • 主要區域市場有哪些？
  • 以產品來看，市場區隔是如何計算的？
  • 按應用領域分類的市場區隔如何？
  • 該產業價值鏈包含哪些不同階段？
  • 該行業的主要促進因素和挑戰是什麼？
  • 全球免疫調節藥物市場的結構是怎麼樣的？主要參與者有哪些？
  • 這個行業的競爭有多激烈？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球免疫調節劑市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品分類

  • 免疫抑制劑
    • 主要部分
      • 抗體
      • Calcineurin抑制劑
      • 糖皮質激素
      • 抗代謝物
      • 其他
  • 活化
    • 主要部分
      • 疫苗
      • 抗體
      • 其他

第7章 市場區隔：依應用領域分類

  • 腫瘤學
  • 呼吸系統
  • HIV
  • 其他

第8章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章 SWOT 分析

第10章：價值鏈分析

第11章：波特五力分析

第12章：價格分析

第13章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Amgen Inc.
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
Product Code: SR112026A4055

The global immunomodulators market size reached USD 232.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 348.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.45% during 2026-2034.

Immunomodulators are a group of drugs used to modify an immune response against infectious diseases, immunodeficiency, and alterations in antibody transfer. These drugs generally include monoclonal antibodies, cytokines , levamisole, and Bacillus Calmette-Guerin (BCG). They are widely used to treat cancer, asthma, tumors, hereditary angioedema, and autoimmune disorders like pemphigus, lupus, allergies, and rheumatoid arthritis. Nowadays, several healthcare providers are recommending immunomodulators with other agents, such as biologics, for managing inflammatory bowel disease (IBD).

IMMUNOMODULATORS MARKET TRENDS:

The unhealthy lifestyles of individuals on account of rapid urbanization, inflating income levels, and the increasing consumption of processed food products has led to a significant rise in the prevalence of chronic diseases worldwide. This is further escalating the need for organ transplantation, which is positively influencing the demand for topical immunomodulators as a promising therapeutic agent in organ transplant recipients. Moreover, the rising aging population and the growing number of accidents are also increasing the risk of organ failure. Consequently, several governing and non-governing authorities are encouraging organ donation, which, in turn, is boosting the sales of topical immunomodulators worldwide. Apart from this, the increasing prevalence of IBD and autoimmune disorders is bolstering the market growth. Immunomodulators are also utilized in combination therapy to decrease the long-term need for steroids and prevent recurring flares and treat diseases that do not respond to antibiotics. Furthermore, several immunomodulators, including Fluvoxamine, Tocilizumab, and Baricitinib with Remdesivir, are finding application for treating hospitalized patients with coronavirus disease (COVID-19). Besides this, several product candidates are currently in late-stage clinical trials. The development of these products is anticipated to expand the applications of immunomodulators for treating various life-threatening diseases.

KEY MARKET SEGMENTATION:

Breakup by Product:

  • Immunosuppressants
    • Antibodies
    • Calcineurin Inhibitors
    • Glucocorticoids
    • Antimetabolites
    • Others
  • Immunostimulants
    • Vaccines
    • Antibodies
    • Others

Breakup by Application:

  • Oncology
  • Respiratory
  • HIV

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

COMPETITIVE LANDSCAPE:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG and Pfizer Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global immunomodulators market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global immunomodulators market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global immunomodulators market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunomodulators Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Immunosuppressants
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Antibodies
      • 6.1.2.2 Calcineurin Inhibitors
      • 6.1.2.3 Glucocorticoids
      • 6.1.2.4 Antimetabolites
      • 6.1.2.5 Others
    • 6.1.3 Market Forecast
  • 6.2 Immunostimulants
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Vaccines
      • 6.2.2.2 Antibodies
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Respiratory
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 HIV
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Biogen Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bristol-Myers Squibb Company
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Eli Lilly and Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 SWOT Analysis
    • 13.3.6 Johnson & Johnson
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Merck & Co. Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Pfizer Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Immunomodulators Market: Major Drivers and Challenges
  • Figure 2: Global: Immunomodulators Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Immunomodulators Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Immunomodulators Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Immunomodulators Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Immunomodulators Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Immunomodulators (Immunosuppressants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Immunomodulators (Immunosuppressants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Immunomodulators (Immunostimulants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Immunomodulators (Immunostimulants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Immunomodulators (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Immunomodulators (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Immunomodulators (Respiratory) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Immunomodulators (Respiratory) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Immunomodulators (HIV) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Immunomodulators (HIV) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Immunomodulators (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Immunomodulators (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: North America: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: North America: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: United States: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: United States: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Canada: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Canada: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Asia-Pacific: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Asia-Pacific: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: China: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: China: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Japan: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Japan: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: India: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: India: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: South Korea: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: South Korea: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Australia: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Australia: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Indonesia: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Indonesia: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Others: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Others: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Europe: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Europe: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Germany: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Germany: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: France: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: France: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: United Kingdom: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: United Kingdom: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Italy: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Italy: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Spain: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Spain: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Russia: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Russia: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Others: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Others: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Latin America: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Latin America: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Brazil: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Brazil: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Mexico: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Mexico: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Others: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Others: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Middle East and Africa: Immunomodulators Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Middle East and Africa: Immunomodulators Market: Breakup by Country (in %), 2025
  • Figure 67: Middle East and Africa: Immunomodulators Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Global: Immunomodulators Industry: SWOT Analysis
  • Figure 69: Global: Immunomodulators Industry: Value Chain Analysis
  • Figure 70: Global: Immunomodulators Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immunomodulators Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Immunomodulators Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Immunomodulators Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Immunomodulators Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 5: Global: Immunomodulators Market: Competitive Structure
  • Table 6: Global: Immunomodulators Market: Key Players